HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

The Lancet Oncology

Volumn 18, Issue 4, 2017, Pages 545-554

  Llombart Cussac, Antonio ^a   Cortés, Javier ^b,d   Paré, Laia ^e,f   Galván, Patricia ^d,e,f   Bermejo, Begoña ^g   Martínez, Noelia ^b   Vidal, Maria ^e,h   Pernas, Sònia ⁱ   López, Rafael ^j   Muñoz, Montserrat ^e   Nuciforo, Paolo ^c   Morales, Serafín ^k   Oliveira, Mafalda ^h   de la Peña, Lorena ^l   Peláez, Alexandra ^l   Prat, Aleix ^d,e,f  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Molecular Genetics Laboratory   (Spain)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^l SOLTI Breast Cancer Research Group   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRURITUS; RASH; SPAIN; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; FOLLOW UP; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; REMISSION INDUCTION; SURVIVAL RATE; TRASTUZUMAB;

EID: 85013679439     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30021-9     Document Type: Article

References (45)

1. 1 Arpino, G, Gutierrez, C, Weiss, H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99 (2007), 694–705.
2. 2 Rimawi, MF, Wiechmann, LS, Wang, Y-C, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17 (2011), 1351–1361.
3. 3 Baselga, J, Cortés, J, Kim, S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366 (2012), 109–119.
4. 4 Blackwell, KL, Burstein, HJ, Storniolo, AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30 (2012), 2585–2592.
5. 5 Swain, SM, Kim, S-B, Cortés, J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14 (2013), 461–471.
6. 6 Gianni, L, Pienkowski, T, Im, Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 25–32.
7. 7 Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet; 379: 633–40.
8. 8 Guarneri, V, Frassoldati, A, Bottini, A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30 (2012), 1989–1995.
9. 9 Piccart-Gebhart, M, Holmes, E, Baselga, J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 34 (2016), 1034–1042.
10. 10 Prat, A, Baselga, J, Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. J Clin Oncol 31 (2013), 1703–1706.
11. 11 Rimawi, MF, Mayer, IA, Forero, A, et al. Multicenter phase ii study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006. J Clin Oncol 31 (2013), 1726–1731.
12. 12 Rimawi, MF, Niravath, PA, Wang, T, et al. TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. Cancer Res, 75(9 suppl), 2015 S6-02-S6 (abstr).
13. 13 Cortés, J, Fumoleau, P, Bianchi, GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 30 (2012), 1594–1600.
14. 14 Carey, LA, Berry, DA, Cirrincione, CT, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 34 (2016), 542–549.
15. 15 Prat, A, Bianchini, G, Thomas, M, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 20 (2014), 511–521.
16. 16 Prat, A, Perou, CM, Deconstructing the molecular portraits of breast cancer. Mol Oncol 5 (2011), 5–23.
17. 17 Prat, A, Pineda, E, Adamo, B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24:suppl 2 (2015), S26–S35.
18. 18 Prat, A, Carey, LA, Adamo, B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst, 106, 2014, dju152.
19. 19 Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
20. 20 Pogue-Geile, KL, Song, N, Jeong, J-H, et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 33 (2015), 1340–1347.
21. 21 Perez, EA, Ballman, KV, Mashadi-Hossein, A, et al. Intrinsic subtype and therapeutic response among HER2-positive breast tumors from the NCCTG (Alliance) N9831 trial. J Natl Cancer Inst, 109, 2016, djw207.
22. 22 Gianni, L, Eiermann, W, Semiglazov, V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375 (2010), 377–384.
23. 23 Prat, A, Cheang, MU, Galván, P, et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. JAMA Oncol 2 (2016), 1287–1294.
24. 24 Vidal, M, Peg, V, Galván, P, et al. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. Mol Oncol 9 (2015), 1081–1090.
25. 25 Symmans, WF, Peintinger, F, Hatzis, C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25 (2007), 4414–4422.
26. 26 Guarneri, V, Frassoldati, A, Bottini, A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30 (2012), 1989–1995.
27. 27 Untch, M, Loibl, S, Bischoff, J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13 (2012), 135–144.
28. 28 Robidoux, A, Tang, G, Rastogi, P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14 (2013), 1183–1192.
29. 29 Untch, M, Rezai, M, Loibl, S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28 (2010), 2024–2031.
30. 30 Schneeweiss, A, Chia, S, Hickish, T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24 (2013), 2278–2284.
31. 31 Untch, M, Fasching, PA, Konecny, GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study Groups. J Clin Oncol 29 (2011), 3351–3357.
32. 32 Slamon, D, Eiermann, W, Robert, N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 (2011), 1273–1283.
33. 33 Slamon, DJ, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001), 783–792.
34. 34 Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005), 1659–1672.
35. 35 Perez, EA, Romond, EH, Suman, VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32 (2014), 3744–3752.
36. 36 Cortazar, P, Zhang, L, Untch, M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384 (2014), 164–172.
37. 37 Perjeta pertuzumab, 2015, European Medicines Agency, London http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002547/WC500141071.pdf (accessed Oct 1, 2016).
38. 38 FDA. FDA approves Perjeta for neoadjuvant breast cancer treatment. Silver Spring, MD: US Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm (accessed Oct 1, 2016).
39. 39 Tolaney, SM, Barry, WT, Dang, CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372 (2015), 134–141.
40. 40 Harris, LN, Ismaila, N, McShane, LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34 (2016), 1134–1150.
41. 41 Whitworth, P, Stork-Sloots, L, de Snoo, FA, et al. Chemosensitivity predicted by BluePrint 80-Gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol 21 (2014), 3261–3267.
42. 42 Dowsett, M, Ebbs, SR, Dixon, JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 23 (2005), 2477–2492.
43. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 54 (2013), 1862–1868.
44. 44 Masuda, N, Sagara, Y, Kinoshita, T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 13 (2012), 345–352.
45. 45 Francis, PA, Regan, MM, Fleming, GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372 (2015), 436–446.